BRIEF—Eisai and Biogen kick off MS co-promotion in Japan

Tokyo’s Eisai and the Japanese arm of Biogen have started co-promoting three multiple sclerosis treatments in Japan.

The deal covers Tecfidera (dimethyl fumarate), Tysabri (natalizumab, genetic recombinant) and Avonex (interferon beta 1a, genetic recombinant).

The firms say they will jointly conduct marketing and medical affairs activities at the clinical facilities for which they are responsible. Biogen Japan will book sales of the products.

Biogen Japan president Shinichi Torii said: “By co-promoting with Eisai who has strong networks in the field of neurology, we believe we can reliably deliver multiple sclerosis treatments to patients who need them.”